Article
Acetazolamide as a therapeutic alternative for central sleep apnea in pediatric patient with FBXO28 gene mutation: A case report and review of literature.
Sleep medicine - 1 Dec 2024
Sirianansopa Kantisa, Amin Reshma
Abstract excerpt
Central sleep apnea (CSA) is a significant concern in children with neurodevelopmental disorders and genetic syndromes, where conventional treatments such as bilevel positive airway pressure (BiLevelPAP) therapy may be poorly tolerated. Acetazolamide, a carbonic anhydrase inhibitor, is an alternative treatment that induces a metabolic acidosis, which may help stabilize respiratory disturbances by enhancing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
